Bernhard Scheiner

Nov 30, 2024 | mdpi.com | Iuliana Radu |Bernhard Scheiner |Jonas Schropp |Maria Delgado

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 3, 2024 | onlinelibrary.wiley.com | Bernhard Scheiner |Nina Dominik |Mattias Mandorfer

We thank Dr. Kountouras et al. for their interest in our work.1, 2 As outlined in our recent study2 as well as previous work from our group,3 there is little clinical evidence suggesting that levels of coagulation proteins (neither VWF nor the factor VIII/protein C ratio) per se represent disease-driving mechanisms in chronic liver disease. Rather, these factors appear to reflect the natural course of disease as their levels are strongly correlated with liver disease severity.

Jul 2, 2024 | mdpi.com | Vera Himmelsbach |Matthias Jeschke |Christian Lange |Bernhard Scheiner

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Mar 14, 2024 | onlinelibrary.wiley.com | Bernhard Scheiner |Alberto Zanetto |Lorenz Balcar |Nina Dominik

1 INTRODUCTION Von Willebrand factor (VWF) is released from endothelial cells upon activation and is usually significantly elevated in patients with advanced chronic liver disease (ACLD), in whom it is a highly versatile biomarker.

Jan 9, 2024 | fis.uke.de | Bernhard Scheiner |Antonio D'Alessio |Aman Mehan |Giulia Manfredi

IMPORTANCE: Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated. OBJECTIVE: To evaluate the association of immune checkpoint inhibitor (ICI)-based therapies vs BSC with overall survival (OS) of patients with uHCC and CP-B liver dysfunction.